Opioid Use Disorder (OUD) and Pregnancy in Utah by Margetts, Saralyn et al.
Opioid Use Disorder (OUD)
and Pregnancy in Utah
Saralyn Margetts, Erin Fanning Madden, Lauran Hymas, Katie Zaman, Gabriela Murza,  Suzanne Prevedel, and Sandra H. Sulzer
Over the past twenty years, opioid use during pregnancy has become much more
common (Haight et al., 2018). Opioids may be prescribed for pain management or the 
treatment of an opioid use disorder (OUD). For example, methadone or buprenorphine 
are medications recommended for pregnant women with OUD. Opioid use may also 
include misusing prescription painkillers or using illicit drugs such as heroin. Regardless 
of the nature of opioid use, it is important for pregnant women to know how opioid use 
can impact their pregnancy and what treatment options are available.
Basic Facts
Drug overdose is the number one cause of death in Utah for women who recently delivered a 
baby, and 77% of these deaths are due to opioids (Smid et al., 2019). 
While babies cannot be “addicted” to opioids because they lack the social factors necessary for
an addiction diagnosis, babies exposed to opioids in utero, especially illicit opioids like heroin, 
have higher risks of poor growth, premature birth, and opioid withdrawal symptoms (Centers 
for Disease Control [CDC], 2021; Reddy et al., 2017).
Prenatal care and checking a baby’s health after birth is especially important for parents who
use opioids (American College of Obstetrics and Gynecology, 2017; CDC, 2021; Reddy et al., 
2017).
Effective medical treatments for OUD, such as methadone and buprenorphine, can help wom-
en have a healthy pregnancy and reduce the risk of health problems for babies compared to 
babies born to women with untreated OUD (Brogly et al., 2014; CDC, 2021; Jones et al., 
2010; Reddy et al., 2017).
Trends
Between 1999 and 2014, OUD in pregnancy rose at an alarming rate, up over 333% in the 
United States (1.5 to 6.5 per 1,000 delivery ospitalizations). In Utah, the rate of increase was 
even greater, up 825% (0.4 to 3.7 per 1,000 delivery hospitalizations) (Haight et al., 2018).
In a nine-year period between 2005 and 2014, 27 women died of opioid overdose in Utah 
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Healthy Outcomes
With proper medications for opioid use disorder (MOUD) treatment for women during 
pregnancy, babies are at lower risk of being born too early, too small, or having opioid 
withdrawal after birth when exposed to opioids during pregnancy (CDC, 2019).
Mothers who received MOUD were more likely to track their baby’s growth and health 
appropriately and maintain custody than mothers with untreated OUD (Berg et al., 
2008).
Mothers receiving MOUD during pregnancy are more likely to have a baby with a healthy 
birth weight and less likely to deliver their baby prematurely (Berg et al., 2008).






Figure 1. Map for Healthy Outcomes for Mother and Baby
Treatment Resources
Call the Substance Abuse and Mental Health Services Administration (SAMHSA) 
National Helpline: 1-800-662-HELP (4357) – free and confidential, 24/7 treatment 
referral and information, available in English and Spanish.
Find a provider near you using the SAMHSA Opioid Treatment Program Directory:
OTP Directory (samhsa.gov).
Access Pregnancy Resources for Women and Families from the Utah Department
of Health, Maternal and Infant Health Program: https://mihp.utah.gov/opioids.
Use Resources on Opioid Use During
Pregnancy from the Centers for Disease Control and Prevention: https://www.cdc.gov/
pregnancy/ opioids/resources.html.
Local Resources
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